Ponesimod

• Description :

  Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P1, with an IC50 of 6 nM in a radioligand binding assay. Ponesimod activates S1P1-mediated signal transduction with high potency (EC50=5.7 nM) . Ponesimod can protect against lymphocyte-mediated tissue inflammation[1][2][3].

• Product Name Alternative :

  ACT-128800

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  LPL Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/Ponesimod.html

• Purity :

  99.78

• Solubility :

  DMSO : ≥ 100 mg/mL

• Smiles :

  O=C1N(C2=CC=CC=C2C)/C(S/C1=C\C3=CC=C(OC[C@H](O)CO)C(Cl)=C3)=N/CCC

• Molecular Formula :

  C23H25ClN2O4S

• Molecular Weight :

  460.97

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Piali L, et al. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther. 2011 May;337 (2) :547-56.|[2]Bolli MH, et al. 2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists. J Med Chem. 2010 May 27;53 (10) :4198-211.|[3]Brossard P, et al. Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol. 2013 Dec;76 (6) :888-96.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  S1PR1; S1PR3; S1PR4; S1PR5

• CAS Number :

  [854107-55-4]